Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
439.37
+14.38 (3.38%)
At close: May 12, 2025, 4:00 PM
439.33
-0.04 (-0.01%)
After-hours: May 12, 2025, 6:37 PM EDT
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B in the quarter ending March 31, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to $11.10B, up 8.98% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.10B
Revenue Growth
+8.98%
P/S Ratio
10.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
112.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
VRTX News
- 5 days ago - Vertex On Track To Significantly Improve Revenue And Earnings By 2030 - Seeking Alpha
- 6 days ago - Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? - Benzinga
- 6 days ago - Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. - Barrons
- 6 days ago - Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More - Investopedia
- 6 days ago - Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 6 days ago - Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade) - Seeking Alpha
- 7 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug - Reuters